ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Gross of the placeholder expense ratio and trading costs · not investor results
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1LLY | ELI LILLY & CO | Healthcare | $1.34T | 23.75% |
2JNJ | JOHNSON & JOHNSON | Healthcare | $682.52B | 12.07% |
3ABBV | ABBVIE INC | Healthcare | $520.47B | 9.21% |
4UNH | UNITEDHEALTH GROUP INC | Healthcare | $363.01B | 6.42% |
5MRK | MERCK & CO INC | Healthcare | $362.27B | 6.41% |
6TMO | THERMO FISHER SCIENTIFIC INC | Healthcare | $259.15B | 4.58% |
7AMGN | AMGEN INC | Healthcare | $252.64B | 4.47% |
8GILD | GILEAD SCIENCES INC | Healthcare | $208.31B | 3.68% |
9ABT | ABBOTT LABORATORIES | Healthcare | $185.75B | 3.29% |
10PFE | PFIZER INC | Healthcare | $164.33B | 2.91% |
11DHR | DANAHER CORP | Healthcare | $163.33B | 2.89% |
12ISRG | INTUITIVE SURGICAL INC | Healthcare | $152.49B | 2.70% |
13VRTX | VERTEX PHARMACEUTICALS INC | Healthcare | $137.57B | 2.43% |
14BMY | BRISTOL MYERS SQUIBB CO | Healthcare | $127.39B | 2.25% |
15CVS | CVS HEALTH CORP | Healthcare | $114.88B | 2.03% |
16HCA | HCA HEALTHCARE INC | Healthcare | $104.58B | 1.85% |
17CI | CIGNA GROUP | Healthcare | $78.07B | 1.38% |
18COR | CENCORA INC | Healthcare | $66.67B | 1.18% |
19EW | EDWARDS LIFESCIENCES CORP | Healthcare | $60.84B | 1.08% |
20ONC | BEONE MEDICINES LTD | Healthcare | $47.50B | 0.84% |
21LH | LABCORP HOLDINGS INC | Healthcare | $30.23B | 0.53% |
22DGX | QUEST DIAGNOSTICS INC | Healthcare | $28.57B | 0.51% |
23INCY | INCYTE CORP | Healthcare | $24.81B | 0.44% |
24STE | STERIS PLC | Healthcare | $24.61B | 0.44% |
25MEDP | MEDPACE HOLDINGS INC | Healthcare | $18.37B | 0.32% |
26ENSG | ENSIGN GROUP INC | Healthcare | $10.88B | 0.19% |
27KRYS | KRYSTAL BIOTECH INC | Healthcare | $9.06B | 0.16% |
28AMRX | AMNEAL PHARMACEUTICALS INC | Healthcare | $7.56B | 0.13% |
29BLCO | BAUSCH & LOMB CORP | Healthcare | $7.56B | 0.13% |
30IMVT | IMMUNOVANT INC | Healthcare | $7.25B | 0.13% |
31RDNT | RADNET INC | Healthcare | $5.99B | 0.11% |
32CON | CONCENTRA GROUP HOLDINGS PARENT INC | Healthcare | $5.44B | 0.10% |
33EWTX | EDGEWISE THERAPEUTICS INC | Healthcare | $5.02B | 0.09% |
34ICUI | ICU MEDICAL INC | Healthcare | $4.43B | 0.08% |
35PLSE | PULSE BIOSCIENCES INC | Healthcare | $3.84B | 0.07% |
36ARQT | ARCUTIS BIOTHERAPEUTICS INC | Healthcare | $3.48B | 0.06% |
37PBLS | PARABILIS MEDICINES INC | Healthcare | $3.42B | 0.06% |
38NHC | NATIONAL HEALTHCARE CORP | Healthcare | $3.30B | 0.06% |
39GRDN | GUARDIAN PHARMACY SERVICES INC | Healthcare | $3.13B | 0.06% |
40IDYA | IDEAYA BIOSCIENCES INC | Healthcare | $3.04B | 0.05% |
41PRVA | PRIVIA HEALTH GROUP INC | Healthcare | $3.02B | 0.05% |
42VCEL | VERICEL CORP | Healthcare | $2.93B | 0.05% |
43RCUS | ARCUS BIOSCIENCES INC | Healthcare | $2.56B | 0.05% |
44ARDT | ARDENT HEALTH INC | Healthcare | $2.49B | 0.04% |
45MD | PEDIATRIX MEDICAL GROUP INC | Healthcare | $2.45B | 0.04% |
46ALMR | ALAMAR BIOSCIENCES INC | Healthcare | $2.21B | 0.04% |
47PBH | PRESTIGE CONSUMER HEALTHCARE INC | Healthcare | $2.15B | 0.04% |
48KLRA | KAILERA THERAPEUTICS INC | Healthcare | $1.72B | 0.03% |
49KMTS | KESTRA MEDICAL TECHNOLOGIES LTD | Healthcare | $1.70B | 0.03% |
50HCSG | HEALTHCARE SERVICES GROUP INC | Healthcare | $1.69B | 0.03% |
51PAHC | PHIBRO ANIMAL HEALTH CORP | Healthcare | $1.44B | 0.03% |
52LMRI | LUMEXA IMAGING HOLDINGS INC | Healthcare | $1.44B | 0.03% |
53GPCR | STRUCTURE THERAPEUTICS INC | Healthcare | $1.42B | 0.03% |
54LBRX | LB PHARMACEUTICALS INC | Healthcare | $1.37B | 0.02% |
55INVA | INNOVIVA INC | Healthcare | $1.35B | 0.02% |
56KARD | KARDIGAN INC | Healthcare | $1.32B | 0.02% |
57INNV | INNOVAGE HOLDING CORP | Healthcare | $1.28B | 0.02% |
58PNTG | PENNANT GROUP INC | Healthcare | $1.26B | 0.02% |
59IART | INTEGRA LIFESCIENCES HOLDINGS CORP | Healthcare | $1.12B | 0.02% |
60SGP | SPYGLASS PHARMA INC | Healthcare | $1.11B | 0.02% |
61SPTX | SEAPORT THERAPEUTICS INC | Healthcare | $1.08B | 0.02% |
62ODTX | ODYSSEY THERAPEUTICS INC | Healthcare | $966M | 0.02% |
63BVS | BIOVENTUS INC | Healthcare | $915M | 0.02% |
64HSTM | HEALTHSTREAM INC | Healthcare | $867M | 0.02% |
65AURA | AURA BIOSCIENCES INC | Healthcare | $740M | 0.01% |
66CTKB | CYTEK BIOSCIENCES INC | Healthcare | $722M | 0.01% |
67NRC | NRC HEALTH | Healthcare | $565M | 0.01% |
68CBIO | CRESCENT BIOPHARMA INC | Healthcare | $534M | 0.01% |
69ANGO | ANGIODYNAMICS INC | Healthcare | $504M | 0.01% |
70DMAC | DIAMEDICA THERAPEUTICS INC | Healthcare | $503M | 0.01% |
71OBIO | ORCHESTRA BIOMED HOLDINGS INC | Healthcare | $484M | 0.01% |
72EOLS | EVOLUS INC | Healthcare | $475M | 0.01% |
73CARL | CARLSMED INC | Healthcare | $474M | 0.01% |
74MOBI | MOBIA MEDICAL INC | Healthcare | $444M | 0.01% |
75SI | SHOULDER INNOVATIONS INC | Healthcare | $441M | 0.01% |
76PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $423M | 0.01% |
77NPCE | NEUROPACE INC | Healthcare | $413M | 0.01% |
78MASS | 908 DEVICES INC | Healthcare | $407M | 0.01% |
79VMD | VIEMED HEALTHCARE INC | Healthcare | $345M | 0.01% |
80EIKN | EIKON THERAPEUTICS INC | Healthcare | $327M | 0.01% |
81BNTC | BENITEC BIOPHARMA INC | Healthcare | $317M | 0.01% |
82CV | CAPSOVISION INC | Healthcare | $314M | 0.01% |
83TTRX | TURN THERAPEUTICS INC | Healthcare | $310M | 0.01% |
84INFU | INFUSYSTEM HOLDINGS INC | Healthcare | $296M | 0.01% |
85AMWL | AMERICAN WELL CORP | Healthcare | $207M | 0.00% |
86INGN | INOGEN INC | Healthcare | $146M | 0.00% |
87ICCC | IMMUCELL CORP | Healthcare | $93M | 0.00% |
88JYNT | JOINT CORP | Healthcare | $92M | 0.00% |
89NTRB | NUTRIBAND INC | Healthcare | $73M | 0.00% |
90POCI | PRECISION OPTICS CORPORATION INC | Healthcare | $55M | 0.00% |
Full long-leg book as of November 2026 · cap-weighted · total market cap $5.65T. Hypothetical model holdings — not a registered fund’s portfolio.
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 465-name universe at November 2026. Rows: Large ≥ $4.2B, Small < $1.1B. Columns: Value ≥ 0.67, Growth < 0.36 B/M. The dot marks the capital-weighted centroid of the book — 99% toward Large, 82% toward Growth. +4% unclassified (5 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → November 2026; the right-hand end is the same value as the box’s dot. 90 names now. Hypothetical holdings — descriptive, not P&L.
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
With respect to 75% of total assets, no more than 5% may be invested in the securities of any one issuer.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20261113T032607 rows=2198308 asof=202611 issuers=20261113T043645 rates=20261113T043645
Measured on the 2026-11 formation date across 90 holdings (cap-weighted). A different formation date can produce different verdicts.
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 335 monthly observations · about 3.4 in the 99% tail · paired percentile bootstrap over months
The estimators agree, which is mild evidence the number isn’t an artefact of one method.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Did the edge survive the paper coming out?
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 18.0% | 5.9% |
| 3 yearsp.a. | 18.0% | 2.1% |
| 5 yearsp.a. | 12.3% | 12.0% |
| 10 yearsp.a. | 14.3% | 0.4% |
| Since inceptionp.a. | 8.2% | -4.1% |
| Year | Long leg | Long-short |
|---|---|---|
| 202611 mo | 19.5% | 5.5% |
| 2025 | 25.4% | 4.4% |
| 2024 | 6.8% | 12.3% |
| 2023 | 6.3% | -14.9% |
| 2022 | -4.0% | 32.4% |
| 2021 | 25.4% | 21.2% |
| 2020 | 15.5% | -27.8% |
| 2019 | 20.3% | -15.4% |
| 2018 | 10.1% | 8.9% |
| 2017 | 19.8% | -9.9% |
| 2016 | 3.9% | 31.5% |
| 2015 | 3.5% | -5.3% |
| 2014 | 23.4% | -11.2% |
| 2013 | 42.3% | -11.3% |
| 2012 | 13.7% | -11.7% |
| 2011 | 13.3% | 5.4% |
| 2010 | 2.4% | -12.3% |
| 2009 | 12.4% | -27.3% |
| 2008 | -20.6% | 6.3% |
| 2007 | 6.9% | -0.6% |
| 2006 | 7.2% | 7.1% |
| 2005 | 6.8% | 6.4% |
| 2004 | -3.2% | -14.8% |
| 2003 | 11.6% | -21.6% |
| 2002 | -19.6% | 32.4% |
| 2001 | -14.4% | -7.2% |
| 2000 | 37.8% | -32.3% |
| 1999 | -14.5% | -20.6% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through November 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
The Foundry Healthcare StdTurn Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a StdTurn signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.